- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00270075
A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery
May 17, 2011 updated by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recombinant Human Erythropoietin (R-HuEPO) in Non-Anemic Patients Scheduled for Orthopedic or Cardiovascular Surgery, to Facilitate Presurgical Autologous Blood Donation (A Double-blind, Randomized, Dose Finding Study)
The purpose of this study is to determine whether epoetin alfa will enable self-donation of at least 4 units of blood during the 2-week period before surgery (which is a shorter period of time than the conventional 3-week blood donation period before surgery) in patients who are not anemic and who will be undergoing orthopedic or heart and blood vessel surgery.
Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients undergoing orthopedic or heart and blood vessel surgery frequently require blood transfusions both during and after the operation.
Patients often have their own blood collected for this purpose over a standard 3- to 4-week period before surgery.
A large percentage of patients are not able to pre-deposit their own blood for transfusion.
For such patients, an agent that can facilitate self-donation and reduce the need for transfusions from others in less time than the conventional 3 weeks before surgery may improve the overall safety of surgery.
This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate whether epoetin alfa will enable the self-deposit of at least 4 units of blood in the abbreviated presurgical time period of 2 weeks by patients who are not anemic and who are undergoing orthopedic or heart and blood vessel surgery.
The study consists of a 7-day screening period when patients will be tested for eligibility for the study, a 14-day treatment and blood collection period, and a follow-up evaluation period beginning 1 day before surgery and continuing to a study termination visit performed at the patient's discharge from the hospital after surgery.
Eligible patients will be randomly assigned to one of four treatment groups: epoetin alfa 300 units/kilogram (U/kg), epoetin alfa 600 U/kg, placebo to match the volume of epoetin alfa 300 U/kg, or placebo to match the volume of epoetin alfa 600 U/kg, given by injection into a vein.
Twice as many patients will receive treatment with epoetin alfa as will receive treatment with placebo.
A total of 3 doses of study medication will be administered to each patient, one dose given on each of Days 1, 4, and 7 of the study.
Additionally, from Day 1 to Day 14 of the study, all patients will receive 200 milligrams of iron and 5 milligrams of a folate supplement daily by mouth to support red blood cell generation.
On Day 1, before the first dose of study drug, one unit of blood will be collected from each patient and stored for self-donated blood transfusion.
An additional unit of blood will be collected from each patient (before administration of study drug) and stored for self-donated blood transfusion on each of Days 4, 7, 11, and 14, only if the patient's hemoglobin level is >11.0 g/dL; if a patient's hemoglobin level is <=11.0
g/dL on any of these days, no blood will be collected on that day, although study drug will be given.
A maximum of 5 units of blood will be collected from any patient.
If sufficient units for the planned surgery are not collected, preparations will be made for patients to receive needed units of blood from donors.
The study duration is 14 days, ending before surgery.
Safety evaluations will include laboratory tests, vital signs, and reporting of the incidence of adverse events.
Effectiveness will be evaluated by comparing the number of self-donated units of blood collected within 2 weeks, and the change in hemoglobin level among the different treatment groups from before the start of the study to the end of the study.
The study hypothesis is that in an abbreviated (2-week) period before surgery, epoetin alfa will facilitate collection of at least 4 units of self-donated blood in patients who are not anemic and who are undergoing orthopedic or heart and blood vessel surgery.
Epoetin alfa 300 units/kilogram (U/kg), epoetin alfa 600 U/kg, placebo matching the volume of the 300 U/kg dose, or placebo matching the volume of the 300 U/kg dose, by injection into a vein; given on each of Days 1, 4, and 7 of the study.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Phase 2
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients scheduled for orthopedic or heart and blood vessel surgery
- requirement of 3 or more units of blood
- who are non-anemic (hemoglobin within normal range of 12.0 - 18.0 grams/deciliter)
- having laboratory tests within normal ranges
Exclusion Criteria:
- Patients with history of any primary blood disease
- having signs and symptoms of significant disease/dysfunction, such as signs and symptoms of significant heart and blood vessel disease (in patients undergoing orthopedic surgery) or severe alteration in rhythm of the heartbeat, persistent brief attacks of chest pain, or significant heart failure in which the heart is unable to maintain adequate circulation of blood (in patients undergoing heart and blood vessel surgery)
- having uncontrolled high blood pressure or signs and symptoms of significant dizziness, faintness, or lightheadedness which appear only on standing and are caused by low blood pressure
- who have received a blood transfusion within 1 month before the start of the study
- having a body weight greater than 100 kilograms (approximately 220 pounds)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Number of self-donated units of blood collected within 2 weeks; Change in hemoglobin level from before the start of the study to the end of the study
|
Secondary Outcome Measures
Outcome Measure |
---|
Changes in safety parameters (laboratory tests, vital signs, physical examination, and adverse events) from before the study to the end of the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 1990
Study Completion (Actual)
May 1, 1992
Study Registration Dates
First Submitted
December 22, 2005
First Submitted That Met QC Criteria
December 22, 2005
First Posted (Estimate)
December 26, 2005
Study Record Updates
Last Update Posted (Estimate)
May 18, 2011
Last Update Submitted That Met QC Criteria
May 17, 2011
Last Verified
February 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR005896
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Transfusion
-
Wellspect HealthCareCompletedArthroplasty, Replacement, Knee | Blood Transfusion | Blood Transfusion, AutologousPoland
-
Wellspect HealthCareCompletedBlood Transfusion | Arthroplasty, Replacement, Hip | Blood Transfusion, AutologousAustria, Netherlands, Norway, Spain
-
University of Colorado, DenverCompleted
-
Diskapi Teaching and Research HospitalCompleted
-
Clinic for Cardiovascular Diseases MagdalenaCompleted
-
Dartmouth-Hitchcock Medical CenterBEST research collaborativeCompletedBlood TransfusionNorway, United States, Australia, Canada, United Kingdom, Brazil
-
Perouse MedicalEclevar MedtechRecruitingChemotherapy | Blood Transfusion | Antibiotics | Parenteral Nutrition | Antiviral Drugs | Veinous | Blood Derivatives Transfusion | PMCF StudyFrance
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI); University of Pittsburgh; Strathmore... and other collaboratorsNot yet recruiting
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)Completed
-
Cardiochirurgia E.H.Completed
Clinical Trials on epoetin alfa
-
Hospital de Clinicas de Porto AlegreOswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RSCompletedComparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis
-
MegalabsAzidus LaboratoriesNot yet recruitingAnemia of Chronic Kidney DiseaseUruguay
-
M.D. Anderson Cancer CenterCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.CompletedKidney Diseases | Anemia
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedBlood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Mammaplasty | Cardiovascular Surgical Procedures | Blood Transfusion, Autologous
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.Terminated
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.CompletedCritical Illness | Anemia